French researchers have developed a new drug delivery system that could cut the dosing schedule for type 2 diabetes and ...

GlobalData’s report assesses the drugs in the Glucagon Like Peptide 1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.

In a recent article published in Science, researchers reviewed clinical studies on the advantages of glucagon-like peptide-1 (GLP-1) medicines beyond glycemic and weight control. GLP-1 medications ...

GLP-1 stands for glucagon-like peptide 1, a class of injectable drugs originally intended for diabetes but now widely prescribed for weight loss. Novo Nordisk, the manufacturer of Ozempic and ...

New STEP-HFpEF findings presented at this year’s European Society of Cardiology Congress add to the many accolades this ...

A recent study found that over four years, participants taking Wevovy as indicated experienced an average weight loss of 10.2 ...

Ty J. Gluckman, MD, FACC, FAHA, of Providence St. Joseph Health, emphasizes the need for better prevention of cardiovascular risks and discusses upcoming advances in glucagon-like peptide 1 (GLP-1) ...

Novo Nordisk is the leader in the glucagon-like peptide 1 (GLP-1) agonists market with 70% share. The company has notched some big wins with Wegovy this year, opening up several new billion-dollar ...

For patients with type 2 diabetes, treatment with tirzepatide (a dual glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptor agonist) is associated with lower risks for ...

or recombinant human low dose interleukin-2 (LD IL-2), and Glucagon-Like Peptide-1 receptor agonists (GLP-1 RAs). Dr. Arun Swaminathan, Coya’s Chief Business Officer, stated, “There has been ...